


WHAT IS CLAIMED IS:

BEST AVAILABLE COPY

1. A compound having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:


A is selected from the group consisting of:

phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;


B is selected from the group consisting of:

phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;

Het-CH₂-R³ is selected from the group consisting of:



M has the formula:



wherein

L¹ is a bond or C₁₋₆ alkyl optionally substituted with one or more R⁴ groups;

L² is a bond or C₁₋₆ alkyl optionally substituted with one or more R⁴ groups;

Q is selected from the group consisting of:

a) H, b) -NR⁴R⁴, c) -OR⁴, and d) C₁₋₆ alkyl optionally substituted with one or more R⁴ groups; and

W is selected from the group consisting of O and S;

X is selected from the group consisting of:

a) -NR⁴-, b) -NR⁴NR⁴-, and c) -S-;

23 L is C₁₋₆ alkyl optionally substituted with one or more R⁴ groups;

24 R¹, at each occurrence, independently is selected from the group consisting of:

25 a) F, b) Cl, c) Br, d) I, e) -CF₃, f) -OR⁷, g) -CN, h) -NO₂, i) -NR⁷R⁷, j) -C(O)R⁷,
 26 k) -C(O)OR⁷, l) -OC(O)R⁷, m) -C(O)NR⁷R⁷, n) -NR⁷C(O)R⁷, o) -OC(O)NR⁷R⁷,
 27 p) -NR⁷C(O)OR⁷, q) -NR⁷C(O)NR⁷R⁷, r) -C(S)R⁷, s) -C(S)OR⁷, t) -OC(S)R⁷,
 28 u) -C(S)NR⁷R⁷, v) -NR⁷C(S)R⁷, w) -OC(S)NR⁷R⁷, x) -NR⁷C(S)OR⁷,
 29 y) -NR⁷C(S)NR⁷R⁷, z) -C(NR⁷)R⁷, aa) -C(NR⁷)OR⁷, bb) -OC(NR⁷)R⁷,
 30 cc) -C(NR⁷)NR⁷R⁷, dd) -NR⁷C(NR⁷)R⁷, ee) -OC(NR⁷)NR⁷R⁷,
 31 ff) -NR⁷C(NR⁷)OR⁷, gg) -NR⁷C(NR⁷)NR⁷R⁷, hh) -S(O)_pR⁷, ii) -SO₂NR⁷R⁷, and
 32 jj) R⁷;

33 R², at each occurrence, independently is selected from the group consisting of:

34 a) F, b) Cl, c) Br, d) I, e) -CF₃, f) -OR⁷, g) -CN, h) -NO₂, i) -NR⁷R⁷, j) -C(O)R⁷,
 35 k) -C(O)OR⁷, l) -OC(O)R⁷, m) -C(O)NR⁷R⁷, n) -NR⁷C(O)R⁷, o) -OC(O)NR⁷R⁷,
 36 p) -NR⁷C(O)OR⁷, q) -NR⁷C(O)NR⁷R⁷, r) -C(S)R⁷, s) -C(S)OR⁷, t) -OC(S)R⁷,
 37 u) -C(S)NR⁷R⁷, v) -NR⁷C(S)R⁷, w) -OC(S)NR⁷R⁷, x) -NR⁷C(S)OR⁷,
 38 y) -NR⁷C(S)NR⁷R⁷, z) -C(NR⁷)R⁷, aa) -C(NR⁷)OR⁷, bb) -OC(NR⁷)R⁷,
 39 cc) -C(NR⁷)NR⁷R⁷, dd) -NR⁷C(NR⁷)R⁷, ee) -OC(NR⁷)NR⁷R⁷,
 40 ff) -NR⁷C(NR⁷)OR⁷, gg) -NR⁷C(NR⁷)NR⁷R⁷, hh) -S(O)_pR⁷, ii) -SO₂NR⁷R⁷, and
 41 jj) R⁷;

42 R³ is selected from the group consisting of:

43 a) -OR⁷, b) -NR⁷R⁷, c) -C(O)R⁷, d) -C(O)OR⁷, e) -OC(O)R⁷, f) -C(O)NR⁷R⁷,
 44 g) -NR⁷C(O)R⁷, h) -OC(O)NR⁷R⁷, i) -NR⁷C(O)OR⁷, j) -NR⁷C(O)NR⁷R⁷,
 45 k) -C(S)R⁷, l) -C(S)OR⁷, m) -OC(S)R⁷, n) -C(S)NR⁷R⁷, o) -NR⁷C(S)R⁷,
 46 p) -OC(S)NR⁷R⁷, q) -NR⁷C(S)OR⁷, r) -NR⁷C(S)NR⁷R⁷, s) -C(NR⁷)R⁷,
 47 t) -C(NR⁷)OR⁷, u) -OC(NR⁷)R⁷, v) -C(NR⁷)NR⁷R⁷, w) -NR⁷C(NR⁷)R⁷,
 48 x) -OC(NR⁷)NR⁷R⁷, y) -NR⁷C(NR⁷)OR⁷, z) -NR⁷C(NR⁷)NR⁷R⁷, aa) -S(O)_pR⁷,
 49 bb) -SO₂NR⁷R⁷, and cc) R⁷;

50 R⁴, at each occurrence, independently is selected from the group consisting of:

51 a) H, b) =O, c) =S, d) =NR⁵, e) =NOR⁵, f) =N-NR⁵R⁵, g) -OR⁵, h) -NO₂, i) -NR⁵R⁵,
 52 j) -C(O)R⁵, k) -C(O)OR⁵, l) -OC(O)R⁵, m) -C(O)NR⁵R⁵, n) -NR⁵C(O)R⁵,
 53 o) -OC(O)NR⁵R⁵, p) -NR⁵C(O)OR⁵, q) -NR⁵C(O)NR⁵R⁵, r) -C(S)R⁵,

54 s) -C(S)OR⁵, t) -OC(S)R⁵, u) -C(S)NR⁵R⁵, v) -NR⁵C(S)R⁵, w) -OC(S)NR⁵R⁵,
 55 x) -NR⁵C(S)OR⁵, y) -NR⁵C(S)NR⁵R⁵, z) -C(NR⁵)R⁵, aa) -C(NR⁵)OR⁵,
 56 bb) -OC(NR⁵)R⁵, cc) -C(NR⁵)NR⁵R⁵, dd) -NR⁵C(NR⁵)R⁵, ee) -OC(NR⁵)NR⁵R⁵,
 57 ff) -NR⁵C(NR⁵)OR⁵, gg) -NR⁵C(NR⁵)NR⁵R⁵, hh) -S(O)_pR⁵, and ii) R⁵;

58 R⁵, at each occurrence, independently is selected from the group consisting of:

59 a) H, b) C₁₋₆ alkyl, c) -C(O)-C₁₋₆ alkyl, and d) -C(O)O-C₁₋₆ alkyl,

60 wherein any of b) - d) optionally is substituted with one or more R⁶ groups;

61 R⁶, at each occurrence, independently is selected from the group consisting of:

62 a) -OH, b) -OC₁₋₆ alkyl, c) -SH, d) -NO₂, e) -NH₂, f) -NHC₁₋₆ alkyl,

63 g) -N(C₁₋₆ alkyl)₂, h) -C(O)H, i) -C(O)OH, j) -C(O)C₁₋₆ alkyl,

64 k) -OC(O)C₁₋₆ alkyl, l) -C(O)OC₁₋₆ alkyl, m) -C(O)NH₂, n) -C(O)NHC₁₋₆ alkyl,

65 o) -C(O)N(C₁₋₆ alkyl)₂, p) -NHC(O)C₁₋₆ alkyl, and q) -S(O)_pC₁₋₆ alkyl;

66 R⁷, at each occurrence, independently is selected from the group consisting of:

67 a) H, b) C₁₋₆ alkyl, c) C₂₋₆ alkenyl, d) C₂₋₆ alkynyl, e) C₃₋₁₄ saturated, unsaturated, or

68 aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic

69 heterocycle comprising one or more heteroatoms selected from the group consisting

70 of nitrogen, oxygen, and sulfur, g) -C(O)-C₁₋₆ alkyl, h) -C(O)-C₂₋₆ alkenyl,

71 i) -C(O)-C₂₋₆ alkynyl, j) -C(O)-C₃₋₁₄ saturated, unsaturated, or aromatic carbocycle,

72 k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising

73 one or more heteroatoms selected from the group consisting of nitrogen, oxygen,

74 and sulfur, l) -C(O)O-C₁₋₆ alkyl, m) -C(O)O-C₂₋₆ alkenyl,

75 n) -C(O)O-C₂₋₆ alkynyl, o) -C(O)O-C₃₋₁₄ saturated, unsaturated, or aromatic

76 carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic

77 heterocycle comprising one or more heteroatoms selected from the group consisting

78 of nitrogen, oxygen, and sulfur,

79 wherein any of b) - p) optionally is substituted with one or more R⁸ groups;

80 R⁸, at each occurrence, is independently selected from the group consisting of:

81 a) F, b) Cl, c) Br, d) I, e) =O, f) =S, g) =NR⁹, h) =NOR⁹, i) =N-NR⁹R⁹, j) -CF₃, k) -

82 OR⁹, l) -CN, m) -NO₂, n) -NR⁹R⁹, o) -C(O)R⁹, p) -C(O)OR⁹, q) -OC(O)R⁹,

83 r) -C(O)NR⁹R⁹, s) -NR⁹C(O)R⁹, t) -OC(O)NR⁹R⁹, u) -NR⁹C(O)OR⁹,

84 v) -NR⁹C(O)NR⁹R⁹, w) -C(S)R⁹, x) -C(S)OR⁹, y) -OC(S)R⁹, z) -C(S)NR⁹R⁹,

85 aa) -NR⁹C(S)R⁹, bb) -OC(S)NR⁹R⁹, cc) -NR⁹C(S)OR⁹, dd) -NR⁹C(S)NR⁹R⁹,

86 ee) $-C(NR^9)R^9$, ff) $-C(NR^9)OR^9$, gg) $-OC(NR^9)R^9$, hh) $-C(NR^9)NR^9R^9$,
 87 ii) $-NR^9C(NR^9)R^9$, jj) $-OC(NR^9)NR^9R^9$, kk) $-NR^9C(NR^9)OR^9$,
 88 ll) $-NR^9C(NR^9)NR^9R^9$, mm) $-S(O)_pR^9$, nn) $-SO_2NR^9R^9$, and oo) R^9 ;

89 R^9 , at each occurrence, independently is selected from the group consisting of:

90 a) H, b) C_{1-6} alkyl, c) C_{2-6} alkenyl, d) C_{2-6} alkynyl, e) C_{3-14} saturated, unsaturated, or
 91 aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic
 92 heterocycle comprising one or more heteroatoms selected from the group consisting
 93 of nitrogen, oxygen, and sulfur, g) $-C(O)-C_{1-6}$ alkyl, h) $-C(O)-C_{2-6}$ alkenyl,
 94 i) $-C(O)-C_{2-6}$ alkynyl, j) $-C(O)-C_{3-14}$ saturated, unsaturated, or aromatic carbocycle,
 95 k) $-C(O)-3-14$ membered saturated, unsaturated, or aromatic heterocycle comprising
 96 one or more heteroatoms selected from the group consisting of nitrogen, oxygen,
 97 and sulfur, l) $-C(O)O-C_{1-6}$ alkyl, m) $-C(O)O-C_{2-6}$ alkenyl,
 98 n) $-C(O)O-C_{2-6}$ alkynyl, o) $-C(O)O-C_{3-14}$ saturated, unsaturated, or aromatic
 99 carbocycle, and p) $-C(O)O-3-14$ membered saturated, unsaturated, or aromatic
 100 heterocycle comprising one or more heteroatoms selected from the group consisting
 101 of nitrogen, oxygen, and sulfur,

102 wherein any of b) – p) optionally is substituted with one or more moieties
 103 selected from the group consisting of:

104 a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OH$, g) $-OC_{1-6}$ alkyl, h) $-SH$,
 105 i) $-SC_{1-6}$ alkyl, j) $-CN$, k) $-NO_2$, l) $-NH_2$, m) $-NHC_{1-6}$ alkyl,
 106 n) $-N(C_{1-6} \text{ alkyl})_2$, o) $-C(O)C_{1-6}$ alkyl, p) $-OC(O)C_{1-6}$ alkyl,
 107 q) $-C(O)OC_{1-6}$ alkyl, r) $-C(O)NH_2$, s) $-C(O)NHC_{1-6}$ alkyl,
 108 t) $-C(O)N(C_{1-6} \text{ alkyl})_2$, u) $-NHC(O)C_{1-6}$ alkyl, v) $-SO_2NH_2$,
 109 w) $-SO_2NHC_{1-6}$ alkyl, x) $-SO_2N(C_{1-6} \text{ alkyl})_2$, and
 110 y) $-S(O)_pC_{1-6}$ alkyl;


111 m is 0, 1, 2, 3, or 4;

112 n is 0, 1, 2, 3, or 4; and


113 p, at each occurrence, independently is 0, 1, or 2,

114 and wherein the compound does not have the formula selected from the group consisting


115 of:



116




117



118

- 1 2. The compound according to claim 1, having the formula:




2

- 3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

- 4 wherein A, B, L, M, R¹, R², R³, X, m, and n are defined as described in claim 1.

- 1 3. The compound according to claim 1 or 2, having the formula:



2

- 3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

- 4 wherein A, B, L, M, R¹, R², R³, X, m, and n are defined as described in claim 1.

- 1 4. The compound according to any one of claims 1-3, wherein


- 2 A is selected from the group consisting of phenyl and pyridyl;

- 3 B is selected from the group consisting of phenyl and pyridyl;

- 4 m is 0, 1, or 2; and


5 n is 0, 1, or 2.

1 5. The compound according to any one of claims 1-4, wherein A-B is:




2
3 wherein A, R², and n are defined as described in claim 1.

1 6. The compound according to claim 5, wherein A-B is:




2
3 wherein A is defined as described in claim 1.

1 7. The compound according to claim 5, wherein A-B is:




2
3 wherein A is defined as described in claim 1.

1 8. The compound according to any one of claims 1-7, wherein A-B is:



2
3 wherein B is defined as described in claim 1.

1 9. The compound according to any one of claims 1-7, wherein A-B is:




2
3 wherein B is defined as described in claim 1.

1 10. The compound according to any one of claims 1-9, wherein R³ is -NHC(O)R⁷.


1 11. The compound according to claim 10, wherein R³ is -NHC(O)CH₃.

1 12. The compound according to any one of claims 1-9, wherein R³ is:



2

- 1 13. The compound according to claim 1 or 2, having the formula:




2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

4 wherein A, B, L, M, R¹, R², X, m, and n are defined as described in claim 1.

- 1 14. The compound according to claim 1 or 2, having the formula:




2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

4 wherein A, L, M, R¹, R³, X, and m are defined as described in claim 1.

- 1 15. The compound according to claim 14, having the formula:




2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

4 wherein A, L, M, R¹, X, and m are defined as described in claim 1.

- 1 16. The compound according to claim 14, having the formula:




2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,

4 wherein L, M, R³, and X are defined as described in claim 1.

- 1 17. The compound according to claim 16, having the formula:




2

3 or a pharmaceutically acceptable salt, ester or prodrug thereof,


wherein L, M, and X are defined as described in claim 1.

18. The compound according to claim 14, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein L, M, R³, and X are defined as described in claim 1.

19. The compound according to claim 18, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein L, M, and X are defined as described in claim 1.

20. The compound according to claim 1 or 2, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R¹, R³, X, and m are defined as described in claim 1.

21. The compound according to claim 20, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R¹, X, and m are defined as described in claim 1.

22. The compound according to claim 20, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
 wherein L, M, R³, and X are defined as described in claim 1.

23. The compound according to claim 22, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
 wherein L, M, and X are defined as described in claim 1.

24. The compound according to claim 20, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
 wherein L, M, R³, and X are defined as described in claim 1.

25. The compound according to claim 24, having the formula:




or a pharmaceutically acceptable salt, ester or prodrug thereof,
 wherein L, M, and X are defined as described in claim 1.

26. The compound according to any one of claims 1-25, wherein M is:




and R⁴, at each occurrence, independently is defined as described in claim 1.

27. The compound according to claim 26, wherein M is:




and R^4 is defined as described in claim 1.

28. The compound according to any one of claims 1-25, wherein M is:



and R^4 , at each occurrence, independently is defined as described in claim 1.

29. The compound according to claim 28, wherein M is:



and R^4 is defined as described in claim 1.

30. The compound according to any one of claims 1-29, wherein X is $-NH-$.

31. The compound according to any one of claims 1-29, wherein X is:



32. A compound having the structure corresponding to any one of the structures listed in Table 1, or a pharmaceutically acceptable salt, ester, or prodrug thereof.

33. A pharmaceutical composition comprising one or more compounds according to any one of claims 1-32 and a pharmaceutically acceptable carrier.

34. A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

35. A method of treating a fungal infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

36. A method of treating a parasitic disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to any one of claims 1-32.

1 37. A method of treating a proliferative disease in a mammal comprising the step of
2 administering to the mammal an effective amount of one or more compounds according to any
3 one of claims 1-32.

1 38. A method of treating a viral infection in a mammal comprising the step of administering
2 to the mammal an effective amount of one or more compounds according to any one of claims
3 1-32.

1 39. A method of treating an inflammatory disease in a mammal comprising the step of
2 administering to the mammal an effective amount of one or more compounds according to any
3 one of claims 1-32.

1 40. A method of treating a gastrointestinal motility disorder in a mammal comprising the step
2 of administering to the mammal an effective amount of one or more compounds according to any
3 one of claims 1-32.

1 41. A method of treating a disorder in a mammal comprising the step of administering to the
2 mammal an effective amount of one or more compounds according to any one of claims 1-32
3 thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group
4 consisting of:

5 a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a
6 urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt
7 infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal
8 infection, a bone infection, a joint infection, a methicillin-resistant *Staphylococcus aureus*
9 infection, a vancomycin-resistant *Enterococci* infection, a linezolid-resistant organism
10 infection, and tuberculosis.

1 42. The method according to any one of claims 34-41, wherein the compound is administered
2 orally, parentally, or topically.

1 43. A method of synthesizing a compound according to any one of claims 1-32.

1 44. A medical device containing one or more compounds according to any one of claims
2 1-32.

1 45. The medical device according to claim 44, wherein the device is a stent.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.